Small Molecule Antibody
The company focuses on yeast molecular biology technology as its research and development direction, and relies on independent innovative technology platforms such as "high-throughput yeast interaction technology", "yeast secretion expression", and "yeast display" to provide a full chain and scenario application solution for yeast
The antigen-binding capacity of nanobodies is similar to conventional antibodies for three reasons. First, the complementarity-determining region 3 (CDR3) of nanobodies is similar or even longer than that of human VH domain (variable domain of heavy immunoglobulin chain).
Do you have a question?
Room 1001, Floor 10, Building 3C, Nanjing Xianlin Zhigu, No. 6 Qimin West Road, Xianlin Street, Qixia District, NanJing, Jiangsu, China, 210033
©2023 Nanjing Ruiyuan Biotechnology Co., Ltd
Get in touch with us!